Ahlers Jeffrey D, Belyakov Igor M
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20817, USA.
Discov Med. 2010 Jun;9(49):528-37.
CD8+ CTL responses are critical for eliminating virus infected cells in acute infection and in controlling virus replication during chronic infection. Despite evidence of potent HIV-1-specific CD8+ CTL responses during the earliest stage of acute infection leading to replacement of founder virus sequence(s) and resolution of peak viral load, in the majority of infected individuals, these responses are inadequate to prevent the establishment or control of persistent infection. Protective CD8+ CTL responses have yet to be achieved by vaccine approaches for HIV-1 or other viruses causing persistent infections, Mycobacterium tuberculosis, malaria, and cancer. Understanding the limitations of CD8+ CTL responses to keep pace with the diversity of rapidly evolving virus in the case of HIV-1 and HCV and to overcome the diverse and complex mechanisms persistent pathogens employ to escape immune recognition should lead to more effective prophylactic and therapeutic approaches for these diseases. Recent technological advances including single genome amplification (SGA) of plasma viral RNA along with direct amplicon sequencing to identify virus quasispecies, bioinformatics, and statistical methods for the systematic identification of HLA-class I associated escape mutations, and mathematical models that better define the kinetics of virus replication and decay, have provided significant insight into mechanisms of viral transmission and sequence evolution, virus-host interactions, and HIV-1 pathogenesis. In this review we attempt to integrate recent findings from studies in HIV-1, persistent virus infections, and cancer that predict effective T cell responses and suggest approaches that could shift the balance of control in favor of the host immune response. Here, we highlight factors considered essential for effective HIV-1 vaccine CD8+ T cell responses: vaccine antigens, quality, magnitude and breadth, mucosal targeting, and formation of CD8+ T cell mucosal memory.
CD8+细胞毒性T淋巴细胞(CTL)反应对于在急性感染中清除病毒感染细胞以及在慢性感染期间控制病毒复制至关重要。尽管有证据表明在急性感染的最早阶段存在强大的HIV-1特异性CD8+ CTL反应,导致原始病毒序列被替换以及病毒载量峰值消退,但在大多数受感染个体中,这些反应不足以预防持续性感染的建立或控制。对于HIV-1或其他导致持续性感染的病毒、结核分枝杆菌、疟疾和癌症,疫苗方法尚未实现保护性CD8+ CTL反应。了解CD8+ CTL反应在HIV-1和丙型肝炎病毒(HCV)情况下与快速进化病毒的多样性保持同步的局限性,以及克服持续性病原体用于逃避免疫识别的各种复杂机制,应该会为这些疾病带来更有效的预防和治疗方法。最近的技术进步,包括血浆病毒RNA的单基因组扩增(SGA)以及直接扩增子测序以识别病毒准种、生物信息学和用于系统识别HLA-I类相关逃逸突变的统计方法,以及能更好地定义病毒复制和衰减动力学的数学模型,为病毒传播和序列进化、病毒-宿主相互作用以及HIV-1发病机制提供了重要见解。在这篇综述中,我们试图整合来自HIV-1、持续性病毒感染和癌症研究的最新发现,这些发现预测了有效的T细胞反应,并提出了可以改变控制平衡以利于宿主免疫反应的方法。在这里,我们强调了对于有效的HIV-1疫苗CD8+ T细胞反应被认为至关重要的因素:疫苗抗原、质量、强度和广度、黏膜靶向以及CD8+ T细胞黏膜记忆的形成。